Corrigendum to "Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease" [Dig. Liver Dis. 48 (2016) 360-370]

Alessandro Armuzzi¹, Paolo Gionchetti², Marco Daperno³, Silvio Danese⁴, Ambrogio Orlando⁵, Maria Lia Scribano⁶, Maurizio Vecchi⁷, Fernando Rizzello⁸; GIVI (Gruppo Italiano su Vedolizumab nelle IBD) Group

Collaborators, Affiliations

Collaborators

GIVI (Gruppo Italiano su Vedolizumab nelle IBD) Group:
Sandro Ardizzone⁹, Alessandro Armuzzi¹⁰, Fabiana Castiglione¹¹, Silvio Danese¹², Marco Daperno¹³, Massimo Fantini¹⁴, Gionata Fiorino¹⁵, Giuseppe Frieri¹⁶, Paolo Gionchetti¹⁷, Luca Neri¹⁸, Ambrogio Orlando¹⁹, Mariabeatrice Principi²⁰, Fernando Rizzello¹⁷, Maria Lia Scribano²¹, Giacomo Carlo Sturniolo²², Maurizio Vecchi²³

Affiliations

¹ IBD Unit, Complesso Integrato Columbus, Fondazione Policlinico Gemelli, Università Cattolica, Rome, Italy.
² DIMEC, University of Bologna, Bologna, Italy.
³ SC Gastroenterologia, AO Ordine Mauriziano, Turin, Italy.
⁴ IBD Center, Humanitas Research Hospital, Rozzano, Milan, Italy.
⁵ Biomedical Department of Internal and Specialist Medicine (DIBIMIS), Division of Medicine, Villa Sofia-V. Cervello Hospital, Palermo University, Palermo, Italy.
⁶ Unit of Gastroenterology, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy.
⁷ Dipartimento di Scienze Biomediche per la Salute, Università di Milano, Milan, Italy.
⁸ DIMEC, University of Bologna, Bologna, Italy. Electronic address: fernando.rizzello@unibo.it.
⁹ Collaborator, S.C. Medicina ad indirizzo epatologico, AO Fatebenefratelli e Oftalmico, Milan, Italy; Collaborator, Department of Gastroenterology, AO Sacco, Milan, Italy.
¹⁰ Steering Committee, IBD Unit, Complesso Integrato Columbus, Fondazione Policlinico Gemelli, Università Cattolica, Rome, Italy; Steering Committee, Department of Internal Medicine and Geriatrics, Università Cattolica del Sacro Cuore, Rome, Italy.
¹¹ Collaborator, Department of Clinical Medicine and Surgery, University of Naples, Napoli, Italy.
¹² Steering Committee, IBD Center, Humanitas Research Hospital, Rozzano, Milan, Italy.
¹³ Steering Committee, SC Gastroenterologia, AO Ordine Mauriziano, Turin, Italy.
¹⁴ Collaborator, Dipartimento di Medicina, UO Gastroenterologia, Università di Roma Tor Vergata, Roma, Italy.
¹⁵ Collaborator, IBD Center, Humanitas Research Hospital, Rozzano, Milan, Italy.
¹⁶ Collaborator, Dipartimento di Medicina Interna e Sanità Pubblica, Università dell'Aquila, Italy.
¹⁷ Steering Committee, IBD Unit, DIMEC, University of Bologna, Italy.
¹⁸ Focus Group Facilitator and Medical Writing, Department of Clinical Science and Community Health, University of Milan, Italy.
¹⁹ Steering Committee, Biomedical Department of Internal and Specialist Medicine (DIBIMIS), Division of Medicine, Villa Sofia-V. Cervello Hospital, Palermo University, Palermo, Italy.
²⁰ Gastroenterology Section, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy.
²¹ Steering Committee, Unit of Gastroenterology, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy.
²² Collaborator, Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche (DiSCOG), Università of Padua, Italy.
²³ Steering Committee, Dipartimento di Scienze Biomediche per la Salute, Università di Milano, Milan, Italy.

PMID: 27555348
DOI: 10.1016/j.dld.2016.06.015

Published Erratum

Corrigendum to "Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease" [Dig. Liver Dis. 48 (2016) 360-370]

Alessandro Armuzzi et al. Dig Liver Dis. 2016 Sep.

. 2016 Sep;48(9):1103.

doi: 10.1016/j.dld.2016.06.015.

Authors

Collaborators

GIVI (Gruppo Italiano su Vedolizumab nelle IBD) Group:
Sandro Ardizzone⁹, Alessandro Armuzzi¹⁰, Fabiana Castiglione¹¹, Silvio Danese¹², Marco Daperno¹³, Massimo Fantini¹⁴, Gionata Fiorino¹⁵, Giuseppe Frieri¹⁶, Paolo Gionchetti¹⁷, Luca Neri¹⁸, Ambrogio Orlando¹⁹, Mariabeatrice Principi²⁰, Fernando Rizzello¹⁷, Maria Lia Scribano²¹, Giacomo Carlo Sturniolo²², Maurizio Vecchi²³

Affiliations

¹ IBD Unit, Complesso Integrato Columbus, Fondazione Policlinico Gemelli, Università Cattolica, Rome, Italy.
² DIMEC, University of Bologna, Bologna, Italy.
³ SC Gastroenterologia, AO Ordine Mauriziano, Turin, Italy.
⁴ IBD Center, Humanitas Research Hospital, Rozzano, Milan, Italy.
⁵ Biomedical Department of Internal and Specialist Medicine (DIBIMIS), Division of Medicine, Villa Sofia-V. Cervello Hospital, Palermo University, Palermo, Italy.
⁶ Unit of Gastroenterology, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy.
⁷ Dipartimento di Scienze Biomediche per la Salute, Università di Milano, Milan, Italy.
⁸ DIMEC, University of Bologna, Bologna, Italy. Electronic address: fernando.rizzello@unibo.it.
⁹ Collaborator, S.C. Medicina ad indirizzo epatologico, AO Fatebenefratelli e Oftalmico, Milan, Italy; Collaborator, Department of Gastroenterology, AO Sacco, Milan, Italy.
¹⁰ Steering Committee, IBD Unit, Complesso Integrato Columbus, Fondazione Policlinico Gemelli, Università Cattolica, Rome, Italy; Steering Committee, Department of Internal Medicine and Geriatrics, Università Cattolica del Sacro Cuore, Rome, Italy.
¹¹ Collaborator, Department of Clinical Medicine and Surgery, University of Naples, Napoli, Italy.
¹² Steering Committee, IBD Center, Humanitas Research Hospital, Rozzano, Milan, Italy.
¹³ Steering Committee, SC Gastroenterologia, AO Ordine Mauriziano, Turin, Italy.
¹⁴ Collaborator, Dipartimento di Medicina, UO Gastroenterologia, Università di Roma Tor Vergata, Roma, Italy.
¹⁵ Collaborator, IBD Center, Humanitas Research Hospital, Rozzano, Milan, Italy.
¹⁶ Collaborator, Dipartimento di Medicina Interna e Sanità Pubblica, Università dell'Aquila, Italy.
¹⁷ Steering Committee, IBD Unit, DIMEC, University of Bologna, Italy.
¹⁸ Focus Group Facilitator and Medical Writing, Department of Clinical Science and Community Health, University of Milan, Italy.
¹⁹ Steering Committee, Biomedical Department of Internal and Specialist Medicine (DIBIMIS), Division of Medicine, Villa Sofia-V. Cervello Hospital, Palermo University, Palermo, Italy.
²⁰ Gastroenterology Section, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy.
²¹ Steering Committee, Unit of Gastroenterology, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy.
²² Collaborator, Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche (DiSCOG), Università of Padua, Italy.
²³ Steering Committee, Dipartimento di Scienze Biomediche per la Salute, Università di Milano, Milan, Italy.

PMID: 27555348
DOI: 10.1016/j.dld.2016.06.015

No abstract available

PubMed Disclaimer

Publication types

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Corrigendum to "Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease" [Dig. Liver Dis. 48 (2016) 360-370]

Collaborators

Affiliations

Corrigendum to "Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease" [Dig. Liver Dis. 48 (2016) 360-370]

Authors

Collaborators

Affiliations

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources